Angiotensin receptor blockers and myocardial infarction - These drugs may increase myocardial infarction - and patients may need to be told

被引：136
作者：
Verma, S [1 ]
Strauss, M
机构：
[1] Toronto Gen Hosp, Div Cardiac Surg, Toronto, ON M5G 2C4, Canada
[2] N York Gen Hosp, Div Cardiol, N York, ON M2K 1E1, Canada
来源：
BMJ-BRITISH MEDICAL JOURNAL | 2004年 / 329卷 / 7477期
关键词：
D O I：
10.1136/bmj.329.7477.1248
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1248 / 1249
页数：2
相关论文
共 12 条
  • [1] Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
    Brenner, BM
    Cooper, ME
    de Zeeuw, D
    Keane, WF
    Mitch, WE
    Parving, HH
    Remuzzi, G
    Snapinn, SM
    Zhang, ZX
    Shahinfar, S
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) : 861 - 869
  • [2] Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE):: a randomised trial against atenolol
    Dahlöf, B
    Devereux, RB
    Kjeldsen, SE
    Julius, S
    Beevers, G
    de Faire, U
    Fyhrquist, F
    Ibsen, H
    Kristiansson, K
    Lederballe-Pedersen, O
    Lindholm, LH
    Nieminen, MS
    Omvik, P
    Oparil, S
    Wedel, H
    [J]. LANCET, 2002, 359 (9311) : 995 - 1003
  • [3] Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors:: the CHARM-Alternative trial
    Granger, CB
    McMurray, JJV
    Yusuf, S
    Held, P
    Michelson, EL
    Olofsson, B
    Östergren, J
    Pfeffer, MA
    Swedberg, K
    [J]. LANCET, 2003, 362 (9386) : 772 - 776
  • [4] IS GSK, 2004, LANCET, V363, P1919
  • [5] Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial
    Julius, S
    Kjeldsen, SE
    Weber, M
    Brunner, HR
    Ekman, S
    Hansson, L
    Hua, TS
    Laragh, J
    McInnes, GT
    Mitchell, L
    Plat, F
    Schork, A
    Smith, B
    Zanchetti, A
    [J]. LANCET, 2004, 363 (9426) : 2022 - 2031
  • [6] Can angiotensin II type 2 receptors have deleterious effects in cardiovascular disease?: Implications for therapeutic blockade of the renin-angiotensin system
    Lévy, BI
    [J]. CIRCULATION, 2004, 109 (01) : 8 - 13
  • [7] Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes
    Lewis, EJ
    Hunsicker, LG
    Clarke, WR
    Berl, T
    Pohl, MA
    Lewis, JB
    Ritz, E
    Atkins, RC
    Rohde, R
    Raz, I
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) : 851 - 860
  • [8] The Study on cognition and prognosis in the elderly (SCOPE): principal results of a randomized double-blind intervention trial
    Lithell, H
    Hansson, L
    Skoog, I
    Elmfeldt, D
    Hofman, A
    Olofsson, B
    Trenkwalder, P
    Zanchetti, A
    [J]. JOURNAL OF HYPERTENSION, 2003, 21 (05) : 875 - 886
  • [9] Blood-pressure reduction and cardiovascular risk in HOPE study
    Sleight, P
    Yusuf, S
    Pogue, J
    Tsuyuki, R
    Diaz, R
    Probstfield, J
    [J]. LANCET, 2001, 358 (9299) : 2130 - 2131
  • [10] Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review
    Strippoli, GFM
    Craig, M
    Deeks, JJ
    Schena, FP
    Craig, JC
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2004, 329 (7470): : 828 - 831
12